Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

NW Bateman; T Abulez; AR Soltis; A McPherson; S Choi; DW Garsed; A Pandey; C Tian; BL Hood; KA Conrads; PN Teng; J Oliver; G Gist; D Mitchell; TJ Litzi; CM Tarney; BA Crothers; P Mhawech-Fauceglia; CL Dalgard; MD Wilkerson; M Pierobon; EF Petricoin; C Yan; D Meerzaman; C Bodelon; N Wentzensen; JSH Lee; DG Huntsman; S Shah; CD Shriver; NT Phippen; KM Darcy; DDL Bowtell; TP Conrads; GL Maxwell; SC Makohon-Moore; W Barakat; X Zhang; A Hunt; W Ao; SL Lytle-Gabbin; Y Casablanca; CA Hamilton; M Newell; J Wells; G Sukumar; D Bacikova; J Freyman; DE Cohn; A Berchuck; L Havrilesky; L Duska; A Odunsi; A Sood; J Brenton; E Sala; C Annunziata; O Dorigo; B Nelson; DR Cochrane; K Moore; E Baldelli; QR Chen; Y Hu; S Fereday; N Traficante; A DeFazio; EL Goode

Journal article

Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

NW Bateman, T Abulez, AR Soltis, A McPherson, S Choi, DW Garsed, A Pandey, C Tian, BL Hood, KA Conrads, PN Teng, J Oliver, G Gist, D Mitchell, TJ Litzi, CM Tarney, BA Crothers, P Mhawech-Fauceglia, CL Dalgard, MD Wilkerson Show all

Npj Precision Oncology | NATURE PORTFOLIO | Published : 2024

DOI: 10.1038/s41698-024-00519-8

Download PDF

Abstract

We performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity. We identified patients with longer progression-free survival had increased immune-related signatures and validated proteins correlating with tumor-infiltrating lymphocytes in 65 tumors from an independent cohort of HGSOC patients, as well as with overall survival in an additional 126 HGSOC patient cohort. We identified that homologous recombination deficient (HRD) tumors are enriched in pathways associated with metabolism and oxidative phosphorylation that we validated in independ..

View full abstract

University of Melbourne Researchers

Dale Garsed Author

David Bowtell Author

Julie Fereday Author

Nadia Traficante Author

Related Projects (2)

IMPROVING OUTCOMES FOR WOMEN WITH EPITHELIAL OVARIAN CANCER

UNDERSTANDING ADVERSE AND EXCEPTIONAL OUTCOMES IN OVARIAN CANCER

Most women with high-grade serous ovarian cancer (HGSC) die within five years of diagnosis, as tumours often develop chemotherapy resistance..

Grants

Awarded by Henry M. Jackson Foundation

Funding Acknowledgements

Our sincere gratitude and appreciation are extended to the patients and family members who participated in the Tissue and Data Acquisition Study of Gynecologic Disease protocol, as well as the staff from Regulatory Affairs, Clinical Data Management and Coordination, Procurement, Processing, and Biobanking at the Inova Health System, Duke University Medical Center, the Ohio State University, Women's Health Integrated Research Center at Inova Health System, and the APOLLO Research Network. We would also like to thank Jonathan Ogata for contributions to figure revisions. Funding for this study was provided in part by the U.S. Department of Defense - Uniformed Services University of the Health Sciences (HU0001-16-2-0006, HU0001-19-2-0031, HU0001-20-2-0033, and HU0001-21-2-0027 to N.T.P. and G.L.M. and HU0001-18-2-0032 to C.D.S.) and the National Health and Medical Research Council of Australia (1092856, 1117044 and 2008781 to D.D.L.B. and 1186505 to D.W.G.). The views expressed herein are those of the authors and do not reflect the official policy of the Uniformed Services University of the Health Sciences, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of Army/Navy/Air Force, Department of Defense, or U.S. Government. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government.